Serveur d'exploration Tocilizumab - Checkpoint (PubMed)

Index « MedMesh.i » - entrée « Sulfasalazine »
Attention, ce site est en cours de développement !
Attention, site généré par des moyens informatiques à partir de corpus bruts.
Les informations ne sont donc pas validées.
Substrate Specificity < Sulfasalazine < Sulfonamides  Facettes :

List of bibliographic references

Number of relevant bibliographic references: 10.
Ident.Authors (with country if any)Title
000335 (2019) Laura Bazzichi [Italie] ; Francesca Nacci [Italie] ; Luigi Sinigaglia [Italie] ; Laura Bianchino [Italie] ; Roberto Caporali [Italie]Subcutaneous tocilizumab alone or with a csDMARD in rheumatoid arthritis patients: subanalysis of Italian data from a multicenter phase IIIb/IV trial.
000A77 (2017) Tsai-Ling Liao [Taïwan] ; Yi-Ming Chen [Taïwan] ; Hung-Jen Liu [Taïwan] ; Der-Yuan Chen [Taïwan]Risk and severity of herpes zoster in patients with rheumatoid arthritis receiving different immunosuppressive medications: a case-control study in Asia.
000C49 (2017) Qingping Yao [États-Unis] ; Bo Shen [États-Unis]A Systematic Analysis of Treatment and Outcomes of NOD2-Associated Autoinflammatory Disease.
000F08 (2016) Maria Gerosa [Italie] ; Tommaso Schioppo [Italie] ; Pier Luigi Meroni [Italie]Challenges and treatment options for rheumatoid arthritis during pregnancy.
000F76 (2015) O. Shovman [Israël] ; Y. Shoenfeld ; P. LangevitzTocilizumab-induced neutropenia in rheumatoid arthritis patients with previous history of neutropenia: case series and review of literature.
001461 (2013) Matthew L. Stoll [États-Unis] ; Randy Q. CronTreatment of juvenile idiopathic arthritis in the biologic age.
001618 (2013) Syed Farhan Bari [Royaume-Uni] ; Afsha Khan ; Tom LawsonC reactive protein may not be reliable as a marker of severe bacterial infection in patients receiving tocilizumab.
001744 (2012) John M. Davis [États-Unis] ; Eric L. MattesonMy treatment approach to rheumatoid arthritis.
001762 (2012) Anne V. Miller [États-Unis] ; Sriya K M. RanatungaImmunotherapies in rheumatologic disorders.
001C03 (2006) H U Scherer [Allemagne] ; G-R Burmester[Biologicals in the treatment of rheumatic diseases].

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/TocilizumabV1/Data/PubMed/Checkpoint
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/MedMesh.i -k "Sulfasalazine" 
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/MedMesh.i  \
                -Sk "Sulfasalazine" \
         | HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd 

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    TocilizumabV1
   |flux=    PubMed
   |étape=   Checkpoint
   |type=    indexItem
   |index=    MedMesh.i
   |clé=    Sulfasalazine
}}

Wicri

This area was generated with Dilib version V0.6.34.
Data generation: Fri May 22 09:34:00 2020. Site generation: Sun Mar 28 09:01:19 2021